Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H16N2O3S |
Molecular Weight | 244.311 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2
InChI
InChIKey=YBJHBAHKTGYVGT-ZKWXMUAHSA-N
InChI=1S/C10H16N2O3S/c13-8(14)4-2-1-3-7-9-6(5-16-7)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)/t6-,7-,9-/m0/s1
Molecular Formula | C10H16N2O3S |
Molecular Weight | 244.311 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: www.ncbi.nlm.nih.gov/pubmed/18356320Curator's Comment: description was created based on several sources, including
www.ncbi.nlm.nih.gov/pubmed/17182796,
www.ncbi.nlm.nih.gov/pubmed/19056639
Sources: www.ncbi.nlm.nih.gov/pubmed/18356320
Curator's Comment: description was created based on several sources, including
www.ncbi.nlm.nih.gov/pubmed/17182796,
www.ncbi.nlm.nih.gov/pubmed/19056639
Biotin (also known as vitamin H and vitamin B7) is a water-soluble vitamin which is required for normal cellular functions, growth and development. Biotin is an important cofactor for many mitochondria and cytoplasm enzymes: acetyl-CoA carboxylase a (ACCa),7 ACCb, pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCC), and methylcrotonyl-CoA carboxylase (MCC) and plays critical role in in the intermediate metabolism of gluconeogenesis, fatty acid synthesis, and amino acid catabolism. The vitamin cannot be synthesized by humans and must be obtained from diet. If there is a lack of biotin, an organism starts suffering from biotin deficiency, a condition which is very common among pregnant women, for example. The vitamin deficiency effects hair, nail growth and skin health. For preventing measures, biotin should be taken as a dietary supplement (in a form of vitamin complex or as a pure biotin) which are marketed worldwide under different names. Biotin is a part of many formulations which were approved by FDA.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3098919
Curator's Comment: Biotin was shown to cross the blood brain barrier in rats.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | INFUVITE ADULT Approved UseINFUVITE ADULT is a combination of vitamins indicated for prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition. Launch Date2000 |
|||
Preventing | BIOTIN Approved UseAs a dietary supplement. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
508.5 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
84.8 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
494.9 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
823.8 ng/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
214.6 ng/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
184 ng/mL |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
41 ng/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
91 ng/mL |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1652.4 ng × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
210 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
2315 ng × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4010 ng × h/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
605.1 ng × h/mL |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15 h |
20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15 h |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15 h |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BIOTIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
81% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
81% |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIOTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Prenatal diagnosis and treatment of holocarboxylase synthetase deficiency. | 1999 Feb |
|
Biotin status: which are valid indicators and how do we know? | 1999 Feb |
|
Human placental Na+-dependent multivitamin transporter. Cloning, functional expression, gene structure, and chromosomal localization. | 1999 May 21 |
|
Immunohistochemistry of MMPs and TIMPs. | 2001 |
|
Biosynthesis of biotin and lipoic acid. | 2001 |
|
Neurotrophic actions of novel compounds designed from cyclopentenone prostaglandins. | 2001 Apr |
|
Polymer support for exonucleolytic sequencing. | 2001 Apr 13 |
|
Mu-opioid receptors are present in functionally identified sympathoexcitatory neurons in the rat rostral ventrolateral medulla. | 2001 Apr 23 |
|
An in situ hybridization protocol to detect rare mRNA expressed in neural tissue using biotin-labelled oligonucleotide probes. | 2001 Feb |
|
Two-site ELISA for the quantitative determination of fatty acid synthase. | 2001 Feb |
|
Development and evaluation of an IgM-capture ELISA for detection of recent infection with bluetongue viruses in cattle. | 2001 Feb |
|
Metabotropic glutamate receptor type 1alpha and tubulin assemble into dynamic interacting complexes. | 2001 Feb |
|
In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. | 2001 Feb 1 |
|
Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro. | 2001 Feb 15 |
|
Relationship between serum biotin concentration and moisture content of the sole horn in cows with clinical laminitis or sound hooves. | 2001 Feb 17 |
|
Agonist-stimulated internalisation of the ligand-gated ion channel P2X(1) in rat vas deferens. | 2001 Feb 2 |
|
Mutational analysis of protein substrate presentation in the post-translational attachment of biotin to biotin domains. | 2001 Feb 2 |
|
Azospirillum doebereinerae sp. nov., a nitrogen-fixing bacterium associated with the C4-grass Miscanthus. | 2001 Jan |
|
Projections and pathways of VIP- and nNOS-containing airway neurons in ferret trachea. | 2001 Jan |
|
Trigemino-reticulo-facial and trigemino-reticulo-hypoglossal pathways in the rat. | 2001 Jan 1 |
|
Expression sequence tag-specific full-length cDNA cloning: actin cDNAs. | 2001 Jan 24 |
|
Efferent projections of infralimbic and prelimbic areas of the medial prefrontal cortex in the Japanese monkey, Macaca fuscata. | 2001 Jan 5 |
|
Effects of glucose, vitamins, and DO concentrations on pyruvate fermentation using Torulopsis glabrata IFO 0005 with metabolic flux analysis. | 2001 Jan-Feb |
|
Erbin is a protein concentrated at postsynaptic membranes that interacts with PSD-95. | 2001 Jun 1 |
|
Functional signal peptides bind a soluble N-terminal fragment of SecA and inhibit its ATPase activity. | 2001 Jun 1 |
|
Structural characterization of pyrrolic cross-links in collagen using a biotinylated Ehrlich's reagent. | 2001 Jun 1 |
|
Abnormal thiol reactivity of tropomyosin in essential hypertension and its association with abnormal sodium-lithium countertransport kinetics. | 2001 Mar |
|
Neuroendocrine differentiation in bronchial carcinomas of classic squamous-cell type: an immunohistochemical study of 29 cases applying the tyramide signal amplification technique. | 2001 Mar |
|
In situ hybridization detection of calcitonin mRNA in routinely fixed, paraffin-embedded tissue sections: a comparison of different types of probes combined with tyramide signal amplification. | 2001 Mar |
|
PCR-ELISAs for the detection of Campylobacter jejuni and Campylobacter coli in poultry samples. | 2001 Mar |
|
Molecular characterization of the 5' regulatory region of rat sodium-dependent multivitamin transporter gene. | 2001 Mar |
|
Biotin induces tetramerization of a recombinant monomeric avidin. A model for protein-protein interactions. | 2001 Mar 16 |
|
Metabolic biotinylation of secreted and cell surface proteins from mammalian cells. | 2001 Mar 9 |
|
Sodium ion-translocating decarboxylases. | 2001 May 1 |
|
Coupling mechanism of the oxaloacetate decarboxylase Na(+) pump. | 2001 May 1 |
|
Rotation of a complex of the gamma subunit and c ring of Escherichia coli ATP synthase. The rotor and stator are interchangeable. | 2001 May 4 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: https://cscprivatelabel.com/wp-content/uploads/2016/05/Biotin.pdf
Recommended daily dosage is 10 ml (in a form of infuvite adult) or 1 tablet a day in a form of Biotin dietary supplement (the dosage may vary).
Route of Administration:
Other
Human T lymphoma Jurkat cells and monocytic myeloid U937 cells were incubated with different concentrations of biotin (nM): 0.025, 0.25 and 10, representing plasma levels in biotin-deficient, biotin-sufficient and biotin-supplemented adults. When taken together with folate, biotin synergizes in the repression of pro-inflammatory cytokines and long-terminal repeats (LTRs), mediated by interactions between HLCS and other chromatin proteins.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:20:10 GMT 2023
by
admin
on
Fri Dec 15 15:20:10 GMT 2023
|
Record UNII |
6SO6U10H04
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
2669 (Number of products:7171)
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
||
|
WHO-VATC |
QA11HA05
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
||
|
FDA ORPHAN DRUG |
760720
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
||
|
LOINC |
34398-8
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
||
|
LIVERTOX |
NBK548710
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
||
|
LOINC |
31997-0
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
||
|
DSLD |
22 (Number of products:127)
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
||
|
WHO-ATC |
A11HA05
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
||
|
NCI_THESAURUS |
C45812
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
||
|
LOINC |
1980-2
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6SO6U10H04
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
SUB32335
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
15956
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
63865
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
346
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
373
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
200-399-3
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
DTXSID7022679
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
6SO6U10H04
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
58-85-5
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
1071508
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
1203
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL857
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
m2506
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
BIOTIN
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
1588
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
SUB05841MIG
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
171548
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
100000092789
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
D001710
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
C309
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
DB00121
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
57586
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
PRIMARY | |||
|
314583
Created by
admin on Fri Dec 15 15:20:10 GMT 2023 , Edited by admin on Fri Dec 15 15:20:10 GMT 2023
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|